Exelixis, Inc.

Exelixis, Inc., a Bay Area biotech company valued at $10 billion, has laid off 130 workers as part of a cost-cutting strategy. This decision reflects the company's efforts to streamline operations amid financial pressures. The layoffs occurred recently and are aimed at improving the company's financial health. Exelixis has not specified which departments were affected by these job cuts. The move highlights the challenges faced by biotech firms in the current economic climate.

Exelixis laid off 130 employees companywide in August 2025 when it closed its King of Prussia, Pennsylvania facility, a reduction that included 33 remote employees who reported to California-based managers. The company had hired many remote workers during and after the COVID-19 pandemic and said it was restructuring to concentrate largely on its Alameda, California operations, with expectations to reopen many affected roles as on-site positions at its Alameda headquarters. The cuts were tied to a facility closure and operational consolidation rather than solely performance, and return-to-office decisions were cited as a factor for some remote workers. The article places Exelixis's reduction in the broader industry context of employers favoring on-site or hybrid work to promote collaboration.